Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › pertuzumab

pertuzumab

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of pertuzumab

50 trials tracked of pertuzumab: 16 in phase 3 or 4 and 11 with published results. The most-cited published study has 2157 citations.

50Trials tracked
16Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 1 Phase 3 15 Phase 2 32 Phase 1 1 Other / NA 1
  1. Phase 3 A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) Completed · 2,157 cited
  2. Phase 3 A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Completed · 534 cited
  3. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer Completed · 480 cited
  4. Phase 3 Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel Completed · 193 cited
  5. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer Completed · 114 cited
  6. Phase 3 A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer Completed · 114 cited
Show 44 more trials
  1. Phase 3 A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer Completed · 64 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Completed · 49 cited
  3. Phase 3 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Completed · 31 cited
  4. Phase 3 A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Completed · 20 cited
  5. Phase 3 Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) Completed · 18 cited
  6. Phase 4 Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer Completed
  7. Phase 3 A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) Completed
  8. Phase 3 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Completed
  9. Phase 3 Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer Completed
  10. Phase 3 A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer Completed
  11. Phase 2 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer Completed
  12. Phase 2 A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed
  13. Phase 2 A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer Completed
  14. Phase 2 Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel Completed
  15. Phase 2 Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer Completed
  16. Phase 2 Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer Completed
  17. Phase 2 A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Completed
  18. Phase 2 Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa Completed
  19. Phase 2 A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study Completed
  20. Phase 2 A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer Completed
  21. Phase 2 Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer Completed
  22. Phase 2 A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy Completed
  23. Phase 2 A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer Completed
  24. Phase 2 A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer Completed
  25. Phase 2 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) Completed
  26. Phase 2 Cardiac Safety Study in Patients With HER2 + Breast Cancer Completed
  27. Phase 2 A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer Completed
  28. Phase 2 Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. Completed
  29. Phase 2 A Study of Pertuzumab in Participants With Metastatic Breast Cancer Completed
  30. Phase 2 To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) Completed
  31. Phase 2 Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression Completed
  32. Phase 2 A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer Completed
  33. Phase 2 A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. Completed
  34. Phase 2 A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer Completed
  35. Phase 2 Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy Completed
  36. Phase 2 Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy Completed
  37. Phase 2 My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Completed
  38. Phase 2 A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer Completed
  39. Phase 2 Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Completed
  40. Phase 2 S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery Completed
  41. Phase 2 Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer Completed
  42. Phase 2 Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers Completed
  43. Phase 1 A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Completed
  44. N/A Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer Completed

Showing the 50 most-cited and recently-updated of 50 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Pyrotinib-based regimen achieves pathological complete response after non-response to standard neoadjuvant therapy in HER2+ breast cancer
Rheumatology Sys. Review
Pyrotinib-based regimen achieves pathological complete response after non-response to standard neoadjuvant therapy in HER2+ breast cancer Case shows new drug combo may help breast cancer patient
This case report and literature review describes a patient with HER2+/HR+ breast cancer who achieved total pathological complete response af…
A woman with HER2-positive breast cancer achieved complete response after switching to a pyrotinib-based regimen when standard therapy faile…
Frontiers Jul 25, 2026
Paclitaxel arm achieves 56.4% pathologic complete response compared to 23.7% with endocrine therapy
Oncology RCT
Paclitaxel arm achieves 56.4% pathologic complete response compared to 23.7% with endocrine therapy Trial shows chemotherapy helps shrink early breast cancer more effectively
This Phase II multicenter randomized trial evaluated neoadjuvant trastuzumab and pertuzumab combined with either endocrine therapy or paclit…
A new trial compares using standard chemotherapy versus hormone therapy to shrink tumors before surgery in patients with HER2-positive breas…
Jul 20, 2026
THP shows noninferior pCR rates compared to TCbHP in HER2-positive invasive breast cancer
Oncology RCT
THP shows noninferior pCR rates compared to TCbHP in HER2-positive invasive breast cancer Trial shows omitting carboplatin maintains success in breast cancer
This Phase III randomized controlled trial of 766 women with untreated, stage II and III, HER2-positive invasive breast cancer found that th…
A new clinical trial shows that removing one specific drug can lower severe side effects while maintaining high success rates for certain br…
Jun 12, 2026
Tucatinib plus trastuzumab and pertuzumab improves median PFS to 24.9 months in HER2+ MBC
Oncology RCT
Tucatinib plus trastuzumab and pertuzumab improves median PFS to 24.9 months in HER2+ MBC Trial shows Tucatinib improves progression-free survival for metastatic breast cancer
This Phase III randomized controlled trial of 654 patients with HER2+ metastatic breast cancer found that adding tucatinib to trastuzumab an…
Adding tucatinib to a standard two-drug combination may help patients with HER2+ metastatic breast cancer live longer without their disease …
Jun 12, 2026
FDA Approves Perjeta (pertuzumab) for HER2-Positive Breast Cancer
Oncology FDA Approval
FDA Approves Perjeta (pertuzumab) for HER2-Positive Breast Cancer FDA approves new drug Perjeta for HER2-positive breast cancer
The FDA approved Perjeta (pertuzumab) for use in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer an…
The FDA approved Perjeta (pertuzumab) for HER2-positive breast cancer.
FDA Apr 29, 2026